Under IMI2, any legal entity can become an IMI Associated Partner. This page sets out the benefits of joining us as an Associated Partner, and explains how being an Associated Partner works in practice.
Who can become an Associated Partner?
The Associated Partner category was created with the goal of opening up our activities to a wider range of stakeholders. As such, examples of organisations that could become IMI Associated Partners include philanthropic organisations and charities that run their own health research programmes, as well as organisations working in sectors related to healthcare such as ICT, imaging, diagnostics, animal health, etc.
Benefits of being an Associated Partner
IMI Associated Partners join a vibrant, collaborative health innovation ecosystem, and enjoy benefits such as access to complementary skills, expertise, technology and data; the opportunity to share knowledge and risks in a non-competitive space; and the more efficient use of resources.
As contributors to the project, Associated Partners are involved in the definition of the project, and can participate as observers in IMI Governing Board meetings during discussions relating to the projects they are involved in.
IMI Associated Partners
So far, the following organisations have become IMI Associated Partners:
- Accelerate Diagnostics will contribute under the IMI2 Call 13 topic 3 – The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
- Autism Speaks will contribute to the IMI2 – Call 10 project on autism. They are also involved in the EU-AIMS project.
- Autistica will contribute to the IMI2 - Call 10 project on autism.
- BD Switzerland Sarl will contribute under the IMI2 Call 13 topic 3 – The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
- Bill and Melinda Gates Foundation contributes to the PERISCOPE project on pertussis (whooping cough) vaccines.
- Bio-rad Laboratories will contribute under the IMI2 Call 13 topic 3 – The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
- International Diabetes Federation contributes to the IMI2 – Call 10 project on diabetes
- JDRF contributes to the diabetes projects INNODIA and BEAT-DKD.
- Leona M. and Harry B. Helmsley Charitable Trust contributes to the diabetes project INNODIA.
- Parkinson UK will contribute under the IMI2 Call 13 topic 4 – Mitochondrial Dysfunction in Neurodegeneration and IMI2 Call 13 topic 5 – Support and coordination action for the projects in the neurodegeneration area of the Innovative Medicines Initiative
- Simons Foundation Autism Research Initiative (SFARI) will contribute to the IMI2 – Call 10 project on autism.
- T1D Exchange will contribute to the IMI2 – Call 10 topic on diabetes
- Wellcome Trust will contribute under the IMI2 Call 13 topic 3 – The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use .
Details of how to become an Associated Partner can be found in this information guide.
In summary, organisations wishing to become Associated Partners must apply to the IMI Governing Board with a letter of endorsement (see templates below). In the letter, applicants should set out their acceptance of the IMI2 Statutes; commit to supporting the objectives of IMI2 in their specific area of research; and set out details of their contribution to IMI (e.g. in-kind/cash contributions, activities, duration, etc.). Organisations are requested to use the following templates to prepare their letters:
- Template for organisations that want to apply to become Associated Partners - doc pdf
- Template for existing Associated Partners that want to apply to expand the scope of their association, e.g. by contributing to a new Call topic or an existing project - doc pdf
To discuss the Associated Partner option in more detail, contact us